Mainstream

Belite Bio targets NDA submission for Tinlarebant in first half of 2026 amid strong cash runway and Phase III progress

Belite Bio targets NDA submission for Tinlarebant in first half of 2026 amid strong cash runway and Phase III progress

Post ContentblteRead More

You might also be interested in reading DWF Labs Says $31 Billion in RWAs Is Onchain but Less Than 10% Is Active in DeFi.

August 12, 2025
In Mainstream